P70-S6激酶1
基因亚型
核糖体蛋白s6
磷酸化
激酶
生物
PI3K/AKT/mTOR通路
蛋白激酶A
细胞生物学
癌症研究
信号转导
生物化学
蛋白激酶B
基因
作者
Doyil Kim,Argun Akçakanat,Gopal K. Singh,Chandeshwar Sharma,Funda Meric‐Bernstam
标识
DOI:10.1080/08977190802556986
摘要
Ribosomal protein S6 kinase 1 (S6K1), a critical mediator of cell growth, is overexpressed in breast cancer and is associated with poor prognosis. S6K1 has two known isoforms, p85(S6K1) and p70(S6K1). p85(S6K1) is characterized by 23 additional amino acids in the N-terminus of p70(S6K1). This is thought to target p85(S6K1) to the nucleus, while p70(S6K1) is mainly cytoplasmic. We sought to determine the activation, regulation, and function of p70(S6K1) and p85(S6K1) in breast cancer. We found that most breast cancer cell lines expressed both isoforms. Mitogen-dependent pathways concordantly regulated phosphorylation on T389, S371, and T421/S424. Phosphorylation of both isoforms was inhibited by PI3K/mTOR inhibitors. Mitogen-dependent pathways concordantly regulated the phosphorylation of the two isoforms on T389, S371, and T421/S424. Both isoforms had S6 kinase activity. We also detected a p60 isoform with antibodies to the p70(S6K1) C-terminal but not the N-terminal. Further studies on S6K1 isoforms are warranted for therapeutically targeting this pathway.
科研通智能强力驱动
Strongly Powered by AbleSci AI